| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.10B | 1.13B | 1.13B | 1.10B | 1.08B | 886.86M |
| Gross Profit | 246.51M | 253.34M | 195.11M | 191.86M | 212.58M | 114.85M |
| EBITDA | 79.94M | 103.17M | 10.02M | 52.22M | 203.57M | -180.18M |
| Net Income | 33.71M | 52.74M | -38.60M | -402.00K | 144.12M | -175.73M |
Balance Sheet | ||||||
| Total Assets | 5.55B | 5.57B | 5.63B | 5.70B | 6.19B | 4.65B |
| Cash, Cash Equivalents and Short-Term Investments | 4.02B | 3.89B | 65.90M | 3.75B | 4.19B | 3.01B |
| Total Debt | 436.84M | 442.26M | 444.31M | 446.99M | 445.83M | 304.83M |
| Total Liabilities | 4.25B | 4.37B | 4.52B | 4.60B | 4.76B | 3.31B |
| Stockholders Equity | 1.30B | 1.20B | 1.11B | 1.10B | 1.43B | 1.35B |
Cash Flow | ||||||
| Free Cash Flow | -18.23M | -19.73M | -54.67M | -34.19M | 70.13M | 84.86M |
| Operating Cash Flow | -12.71M | -10.71M | -49.88M | -29.84M | 73.97M | 92.34M |
| Investing Cash Flow | 37.26M | 10.67M | 141.14M | -62.00M | -85.53M | -8.48M |
| Financing Cash Flow | -15.39M | -10.97M | -55.31M | -21.80M | -60.62M | -43.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $927.19M | 8.57 | 13.21% | 1.73% | 12.22% | 120.73% | |
75 Outperform | $1.13B | 12.91 | 9.97% | 4.79% | 13.35% | 16.56% | |
74 Outperform | $918.88M | 7.73 | 27.34% | 2.29% | 4.61% | 73.40% | |
68 Neutral | $576.89M | 6.83 | 29.35% | ― | 16.34% | -1.26% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
62 Neutral | $709.28M | 8.19 | 15.10% | 3.59% | 0.93% | 224.95% | |
55 Neutral | $1.24B | 36.72 | 2.66% | ― | -3.35% | -21.82% |
ProAssurance Corporation is a leading specialty insurer with a focus on medical professional liability and workers’ compensation insurance, operating primarily in the eastern United States.
On November 4, 2025, ProAssurance Corporation reported its financial results for the third quarter of 2025, with a net income of $1.4 million and operating income of $7.9 million. The company continues to make progress in adjusting premium rates to match challenging market conditions. The announcement also highlighted an 8% increase in Specialty P&C renewal premiums and a consolidated Non-GAAP combined ratio of 112.2% for the quarter. ProAssurance is in the process of merging with The Doctors Company, with regulatory approvals pending in several states, and anticipates closing the transaction by June 30, 2026.
The most recent analyst rating on (PRA) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on ProAssurance stock, see the PRA Stock Forecast page.